Welcome to our dedicated page for PRESSURE BIOSCIENCES news (Ticker: PBIO), a resource for investors and traders seeking the latest updates and insights on PRESSURE BIOSCIENCES stock.
Pressure BioSciences, Inc. (PBIO) is a forefront life sciences company that focuses on the development and commercialization of an innovative platform technology known as Pressure Cycling Technology (PCT). This technology employs cycles of hydrostatic pressure, ranging from ambient to ultra-high levels (up to 35,000 psi and beyond), to precisely control biomolecular interactions, offering significant advancements in various scientific fields.
The company's core business revolves around leveraging PCT to enhance the analysis, study, and manipulation of biological samples. This technology has broad applications in areas such as protein characterization, pathogen inactivation, and the preparation of samples for genomic and proteomic studies. By utilizing PCT, researchers and scientists can achieve higher yields, improved quality, and better consistency in their biological analyses.
Recently, PBIO has made notable strides with the introduction of its new consumer products business unit, Uncle Bud’s. In January 2024, the company kicked off with a substantial $252,000 shipment of its Sunburn Soother to one of the world’s largest retailers, showcasing strong market demand and consumer interest. Additionally, VICAR Holdings LLC has committed to purchasing over 10,000 bottles of PBIO's best-in-class Nano-CBD topical spray in 2024, indicating a promising trajectory for their consumer products segment.
PBIO's relocation to a new facility has significantly increased their manufacturing space, enhanced operating efficiencies, and achieved measurable cost savings, setting the stage for unencumbered growth through multi-year expansion plans. The new facility is expected to support the company's long-term strategy and scale operations to meet growing demand.
Uncle Bud's acquisition has already yielded early synergies and measurable performance metrics within the first month, boosting PBIO's market presence and consumer engagement. This positive momentum highlights PBIO's capability to integrate and scale operations effectively.
Furthermore, Pressure BioSciences’ UltraShear platform continues to showcase its potential by enabling the development and launch of health and wellness products with groundbreaking bioavailability, fast onset, and effectiveness. This platform technology is a testament to PBIO's commitment to innovation and enhancing the quality and effectiveness of bio-molecular research and consumer applications.
Pressure BioSciences, Inc. (PBIO) reported a significant milestone as its subsidiary, PBI Agrochem, shipped an initial eco-friendly agrochemical order valued at $130,000. This order marks the beginning of a promising demand pipeline for its environmentally responsible nematode control products. With the global shift towards sustainable farming practices, PBI aims to capitalize on the growing preference for natural agrochemicals over synthetic options. The company is also experiencing strong sales momentum, highlighted by a recent $1.5 million order for CBD product production. CEO Richard Schumacher emphasized plans for a potential NASDAQ or NYSE listing in 2023, indicating strong growth prospects.
Pressure BioSciences, Inc. (OTCQB:PBIO) has entered a manufacturing and distribution agreement with CBD Supply MD, projected to generate over $1.5 million in revenue during 2023. The deal involves supplying UltraShear™ optimized nanoemulsified CBD products, starting with an initial shipment of 850 vials by mid-April 2023. This collaboration aims to enhance product effectiveness with rapid absorption and high potency. Executives from both companies expressed confidence in the partnership's potential, highlighting the advanced technology's unique benefits and market needs. PBIO is also planning to uplist to NASDAQ or NYSE later in the year.
Pressure BioSciences (OTCQB:PBIO) announced a significant equity exchange where its largest investor converted over $10 million in senior secured debt into unsecured preferred stock. This exchange, valued at $2.50 per share, represents more than 50% of the total debt owed to this investor and around 30% of PBIO's overall debt. The company noted recent advancements in its Ultra Shear Technology, enhancing products in cosmeceuticals and sports recovery sectors. CEO Richard T. Schumacher expressed optimism about the company's future and the potential for further debt-to-equity conversions from other investors.
Pressure BioSciences, Inc. (OTCQB:PBIO) announced a significant milestone with a prepaid order from PRS International Trade for 16 Barocycler EXT units totaling nearly $600,000. This marks the largest single order in the company's history, reflecting strong demand for its Pressure Cycling Technology (PCT) products. The company expects this order will contribute to a robust first quarter in 2023, alongside increasing global sales for its pressure-based instruments and its new UltraShear nanoemulsions platform. CEO Richard T. Schumacher emphasized the potential for substantial revenue growth this year as the company expands its market reach into China and other regions.
Pressure BioSciences, Inc. (OTCQB: PBIO) has partnered with One World Products, Inc. (OTCQB: OWPC) to innovate a new line of CBD-infused sports performance and recovery drinks. This collaboration aims to utilize PBIO's UltraShear nanoemulsification technology to enhance the bioavailability of CBD and improve recovery times for athletes. The sports performance drink market was valued at approximately $9.5 billion in 2021. The venture targets both athletes and non-athletes, leveraging trends in health and wellness. The partnership is positioned to offer competitive advantage over existing products by enabling faster absorption of ingredients.
Pressure BioSciences, Inc. (OTCQB:PBIO) announced positive results from consumer testing of its THC Nanoemulsion Oral Spray, developed using its Ultra Shear Technology (UST). The spray demonstrated quick onset, with effects noted as soon as 1-10 minutes and peaks within 15-60 minutes, addressing issues with traditional THC edibles that delay effects. The product aims to disrupt the cannabis market by offering reliable dosing without respiratory risks associated with smoking or vaping. PBI anticipates significant revenue from its California partners as they prepare for product launch this quarter.
Pressure BioSciences, Inc. (PBIO) anticipates significant revenue growth in 2023, driven by its newly launched Ultra Shear Technology™ (UST). The company predicts Q4 2022 revenue to be the highest in four years and expects continuous quarter-over-quarter growth in 2023. Key agreements including four executed that could yield over $1M annually each, alongside anticipated strong performance in UltraShear Nano-CBD and other products, are set to enhance profitability. Management aims for breakeven by the end of the year and plans to uplist to a national exchange.
Pressure BioSciences, Inc. (OTCQB:PBIO) announced the receipt of a $75,000 payment for the first commercial lot of a CBD oral spray developed with its Ultra Shear Technology™. This product is part of a multi-year agreement with Safer Medical of Montana, targeting rapid absorption and high potency for the U.S. veterans community. The company expects revenues exceeding $1 million in Q1/Q2 2023 from subsequent phases of this agreement, emphasizing significant growth potential in various sectors, including pharmaceuticals and nutraceuticals.
Pressure BioSciences, Inc. (OTCQB:PBIO) announced that their collaboration with renowned skincare expert Dr. Adrienne Denese has achieved exceptional results in developing next-gen skincare products. Utilizing their patented Ultra Shear Technology™, PBI has successfully nanoemulsified retinoate and Vitamin C, aiming to enhance bioavailability in Dr. Denese's anti-aging products. Dr. Denese reported unprecedented skin tightening effects and plans to advance the serum into clinical trials. PBI anticipates commercial sales of these products could begin in Q2 2023, leading to significant revenue growth.
Pressure BioSciences (OTCQB:PBIO) reported Q3 2022 total revenue of $144,000, a 72% decline from $518,000 in Q3 2021. Instrument sales fell 66% to $134,000, while agrochem sales dropped 41% to $10,000. Operating loss increased by 10% to $1,363,000. Despite these challenges, the company anticipates a strong Q4, driven by their Ultra Shear Technology (UST) commercialization efforts. Key partnerships and product launches are set for 2023, with projected profitability expected by year-end. Investor call scheduled for November 22, 2022.
FAQ
What is the current stock price of PRESSURE BIOSCIENCES (PBIO)?
What is the market cap of PRESSURE BIOSCIENCES (PBIO)?
What is Pressure BioSciences, Inc. (PBIO)?
What is Pressure Cycling Technology (PCT)?
In which areas is PCT technology applied?
What recent achievements has PBIO made?
What is Uncle Bud’s?
How has PBIO's new facility impacted the company?
What is the UltraShear platform?
How has Uncle Bud’s performed since its acquisition?
What are some applications of PBIO’s products?
What is the significance of PBIO’s consumer products?
